ESMO 2016 Congress

Cancer in Special Situations

07 Oct - 11 Oct 2016, Copenhagen, Denmark

ESMO-Congress-2016-square

The annual ESMO congress is the premier scientific platform to present your oncology research and as such, the ultimate learning experience for congress attendees. Find the abstracts, posters, PDF presentation and webcasts from ESMO 2016 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Special Sessions and Tracks

Useful links





Format available

https://oncologypro.esmo.org/Meeting-Resour...e-perspective-of-the-cost-effectiveness-body

Date: 07 Oct 2016
Presenter: Sarah Garner
Resources: Presentation, Webcast
Topic: Bioethics, Legal, and Economic Issues

https://oncologypro.esmo.org/Meeting-Resour...-stage-resectable-non-small-cell-lung-cancer

BackgroundNivolumab is a PD-1 inhibitor that has demonstrated durable responses and improved survival in patients (pts) with previously treated, metastatic non-small-cell lung cancer (NSCLC).

Date: 07 Oct 2016
Presenter: Patrick Forde
Resources: Abstract, Presentation, Webcast
Topic: Non-Small Cell Lung Cancer

https://oncologypro.esmo.org/Meeting-Resour...e-IB-to-IIIA-NSCLC-final-results-of-CSLC0501

BackgroundAdjuvant chemotherapy is recommended for completely resected stage II-IIIa NSCLC. Indirect comparison meta-analysis of adjuvant vs neoadjuvant therapy showed no difference in survival.

Date: 07 Oct 2016
Presenter: Yi-Long Wu
Resources: Abstract, Presentation, Webcast
Topic: Non-Small Cell Lung Cancer

https://oncologypro.esmo.org/Meeting-Resour.../Invited-discussant-LBA41-and-abstract-1178O

Date: 07 Oct 2016
Presenter: Paul Baas
Resources: Presentation, Webcast
Topic: Thoracic Malignancies

https://oncologypro.esmo.org/Meeting-Resour...line-therapy-for-small-cell-lung-cancer-SCLC

BackgroundAlisertib, a selective AAK inhibitor, showed single-agent antitumor activity in preclinical in vivo SCLC models and was synergistic with P in this setting. We report the efficacy (PFS, OS, ORR) and safety from this study.

Date: 07 Oct 2016
Presenter: Taofeek Owonikoko
Resources: Abstract, Presentation, Webcast
Topic: Small Cell Lung Cancer

https://oncologypro.esmo.org/Meeting-Resour...usions-responding-to-aurora-kinase-inhibitor

BackgroundAlthough there is a high ORR to platin/etoposide, small cell lung carcinoma (SCLC) patients inevitably recur, and second line topotecan has only a 20% ORR.

Date: 07 Oct 2016
Presenter: Siraj Ali
Resources: Abstract
Topic: Small Cell Lung Cancer

https://oncologypro.esmo.org/Meeting-Resour...Invited-discussant-abstracts-1423O-and-1424O

Date: 07 Oct 2016
Presenter: Pilar Garrido Lopez
Resources: Presentation, Webcast
Topic: Thoracic Malignancies

https://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/Introduction8

Date: 07 Oct 2016
Presenter: Evandro de Azambuja
Resources: Presentation, Webcast
Topic: Bioethics, Legal, and Economic Issues

https://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/Conclusions

Date: 07 Oct 2016
Presenter: Matthew Sydes
Resources: Webcast
Topic: Bioethics, Legal, and Economic Issues

https://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/Welcome-by-the-ESMO-PAWG-Chair

Date: 07 Oct 2016
Presenter: Bettina Ryll
Resources: Presentation, Webcast
Topics: Bioethics, Legal, and Economic Issues, Patient Education and Advocacy